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1Background and Purpose—Blend, black hole, island signs, and hypodensities are reported to predict hematoma expansion 
in acute intracerebral hemorrhage. We explored the value of these noncontrast computed tomography signs in predicting 
hematoma expansion and functional outcome in our cohort of intracerebral hemorrhage.
Methods—The TICH-2 (Tranexamic acid for IntraCerebral Hemorrhage-2) was a prospective randomized controlled trial 
exploring the efficacy and safety of tranexamic acid in acute intracerebral hemorrhage. Baseline and 24-hour computed 
tomography scans of trial participants were analyzed. Hematoma expansion was defined as an increase in hematoma 
volume of >33% or >6 mL on 24-hour computed tomography. Poor functional outcome was defined as modified Rankin 
Scale of 4 to 6 at day 90. Multivariable logistic regression was performed to identify predictors of hematoma expansion 
and poor functional outcome.
Results—Of 2325 patients recruited, 2077 (89.3%) had valid baseline and 24-hour scans. Five hundred seventy patients 
(27.4%) had hematoma expansion while 1259 patients (54.6%) had poor functional outcome. The prevalence of 
noncontrast computed tomography signs was blend sign, 366 (16.1%); black hole sign, 414 (18.2%); island sign, 
200 (8.8%); and hypodensities, 701 (30.2%). Blend sign (adjusted odds ratio [aOR] 1.53 [95% CI, 1.16–2.03]; 
P=0.003), black hole (aOR, 2.03 [1.34–3.08]; P=0.001), and hypodensities (aOR, 2.06 [1.48–2.89]; P<0.001) were 
independent predictors of hematoma expansion on multivariable analysis with adjustment for covariates. Black hole 
sign (aOR, 1.52 [1.10–2.11]; P=0.012), hypodensities (aOR, 1.37 [1.05–1.78]; P=0.019), and island sign (aOR, 2.59 
[1.21–5.55]; P=0.014) were significant predictors of poor functional outcome. Tranexamic acid reduced the risk of 
hematoma expansion (aOR, 0.77 [0.63–0.94]; P=0.010), but there was no significant interaction between the presence 
of noncontrast computed tomography signs and benefit of tranexamic acid on hematoma expansion and functional 
outcome (P interaction all >0.05).
Conclusions—Blend sign, black hole sign, and hypodensities predict hematoma expansion while black hole sign, 
hypodensities, and island signs predict poor functional outcome. Noncontrast computed tomography signs did not predict 
a better response to tranexamic acid.
Clinical Trial Registration—URL: https://www.isrctn.com. Unique identifier: ISRCTN93732214.   (Stroke. 2020;51:00-00. 
DOI: 10.1161/STROKEAHA.119.026128.)
Key Words: cerebral hemorrhage ◼ hematoma ◼ odds ratio ◼ prevalence ◼ probability ◼ tranexamic acid
Received July 12, 2019; final revision received August 28, 2019; accepted September 20, 2019.
From the Stroke Trials Unit, Division of Clinical Neuroscience (Z.K.L., A.A., A.B., J.P.A., P.S., L.W., S.P., T.J.E., N.S., P.M.B), Radiological Sciences 
(S.P., R.A.D.), NIHR Nottingham Biomedical Research Centre (RD) and Vascular Medicine, Division of Medical Sciences and GEM (T.J.E.), University 
of Nottingham, United Kingdom; Department of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia (Z.K.L); Department of Stroke, 
Nottingham University Hospitals NHS Trust, United Kingdom (K.K., N.S., P.M.B); School of Medicine, University of Western Australia, Perth, Australia 
(L.A.C.); Department of Neurology, Selcuk University Medical Faculty, Konya, Turkey (S.O.); Institute for Applied Clinical Studies, Keele University, 
Staffordshire, Stoke-on-Trent, United Kingdom (C.R.); Department of Neurology, Semmelweis University, Budapest, Hungary (D.B.); Neurology Unit, 
Azienda Socio Sanitaria Territoriale di Mantova, Mantua, Italy (A.C.); Department of Neurology, Bispebjerg and Frederiksberg Hospital, University 
of Copenhagen (C.O., H.C.); and Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, 
Denmark (C.O.).
The online-only Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.119.026128.
Correspondence to Nikola Sprigg, DM, Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, NG5 1PB Nottingham, United 
Kingdom. Email nikola.sprigg@nottingham.ac.uk
© 2019 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article 
under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original 
work is properly cited.
Noncontrast Computed Tomography Signs as Predictors of 
Hematoma Expansion, Clinical Outcome, and Response to 
Tranexamic Acid in Acute Intracerebral Hemorrhage
Zhe Kang Law, MRCP; Azlinawati Ali, MSc; Kailash Krishnan, PhD; Adam Bischoff, BMedSci;  
Jason P. Appleton, PhD; Polly Scutt, MSc; Lisa Woodhouse, MSc; Stefan Pszczolkowski, PhD;  
Lesley A. Cala, FRCR; Robert A. Dineen, FRCR; Timothy J. England, PhD; Serefnur Ozturk, MD;  
Christine Roffe, MD; Daniel Bereczki, MD; Alfonso Ciccone, MD;  
Hanne Christensen, DMSci; Christian Ovesen, MD; Philip M. Bath, FMedSci; Nikola Sprigg, DM;  
on behalf of TICH-2 Investigators





 http://ahajournals.org by on November 22, 2019
2  Stroke  January 2020
Hematoma expansion complicates up to 38% of patients with acute intracerebral hemorrhage (ICH) within the 
first few hours of onset and leads to higher mortality and mor-
bidity.1 However, given that the majority of patients with ICH 
do not have hematoma expansion, identifying patients at risk 
of hematoma expansion may be important in clinical trials 
testing hemostatic therapies to selectively target patients who 
are most likely to benefit.
Shorter onset-to-computed tomography (CT) time, larger 
baseline hematoma volume, prior antiplatelet and anticoagu-
lant therapy were identified as independent predictors of he-
matoma expansion with C-index of 0.78 (95% CI, 0.75–0.82) 
in a large patient level meta-analysis of data from cohort stud-
ies and randomized trials.2 The predicted probability of he-
matoma expansion increased with larger bleeds and peaked at 
≈75 mL before declining while the probability of hematoma 
expansion was the highest in patients with onset-to-CT time 
of <3 hours.2 CT angiography (CTA) spot sign was reported to 
have a sensitivity of ≈60% and specificity of 90% in predict-
ing hematoma expansion but the addition of spot sign only 
increased the C-index by 0.05.2,3 Furthermore, CTA is not 
routinely performed in patients with ICH. In the TICH-2 trial 
(Tranexamic acid for IntraCerebral Hemorrhage-2), only 10% 
of patients had a baseline CTA.4
Several noncontrast CT (NCCT) signs of heterogeneous 
density and irregular shape have been identified as predic-
tors of hematoma expansion in ICH. The blend sign, black 
hole sign, swirl sign, fluid level, and hypodensities are signs 
of heterogeneous density; another, the island sign, reflects ir-
regular shape.5–10 Heterogeneous density represents areas of 
hyperdense mature blood and hypodense fresh blood indicat-
ing ongoing bleeding,10 while island sign may represent mul-
tifocal bleeding points.7 The universal availability of NCCT 
in patients with ICH and the reportedly excellent inter-rater 
reliability amongst trained assessors (κ, 0.806–0.957) makes 
these signs an attractive alternative to CTA spot sign.5–8 These 
signs have a sensitivity of 31.9% to 44.7% and specificity of 
94.7% to 98.2% for prediction of hematoma expansion.5–8 
However, many source studies were small single-center stud-
ies.5–8 One exception was the Antihypertensive Treatment of 
Acute Cerebral Hemorrhage II, which found NCCT signs to 
be useful predictors of hematoma expansion.11 Several meta-
analyses have found substantial heterogeneity between the 
studies.12,13 Therefore, further studies are needed to evaluate 
the value of NCCT signs.
In the TICH-2 trial, there was no significant difference in 
shift of functional outcome between the tranexamic acid and 
placebo group despite a significant reduction in risk of hema-
toma expansion in the tranexamic acid group.4 In the current 
analysis, we explore the role of some of the NCCT signs as 
predictors of hematoma expansion and poor functional out-
come, and if a subgroup of patients with 1 or more of these 
signs benefited from tranexamic acid.
Methods
The TICH-2 trial was a prospective randomized placebo controlled 
trial testing the efficacy and safety of intravenous tranexamic acid 
in patients with acute spontaneous ICH presenting within 8 hours 
of symptom onset. Details of the trial were previously published.4,14 
Ethics approval was obtained from the local institutional review 
board. Written informed consent was obtained from patients or rela-
tives before enrolment. After publication of the planned primary and 
secondary analyses, the trial data can be shared on reasonable request 
to the corresponding author and trial steering committee.
Image Acquisition
An NCCT was required for the diagnosis of spontaneous ICH before 
recruitment and randomization. All CT brain scans were performed as 
per local protocol. CT scans obtained from any scanner of any man-
ufacturer; any slice thickness with a minimum of an axial view was 
accepted. CT scans with incomplete or missing slices were excluded. 
Baseline scans were performed before randomization. Follow-up 
CT scans were performed at 24±12 hours after the baseline scans.14 
When multiple scans were available, the scan closest to 24 hours 
after randomization was used to determine hematoma expansion. The 
exception was if the 24-hour CT was performed after neurosurgery, 
when a preoperative CT scan was used instead. A participant would 
be excluded from analysis for hematoma expansion if no follow-up 
scans or only postsurgery scans were available.
Image Analysis
Three independent raters blinded to clinical data (Z.K. Law, neu-
rologist; A. Ali, CT radiographer; K. Krishnan, stroke physician) 
performed volumetric measurements using the ITK-SNAP soft-
ware version 3.6.0.15 Intraparenchymal and intraventricular hema-
toma volumes were computed independently using an active contour 
semiautomated segmentation algorithm,15 followed by manual ed-
iting if necessary.
Evaluation of intra- and interrater reliability of hematoma volume 
measurement was performed. Each rater performed 2 measurements 
on the same CT scan at least 1 day apart. In addition, to assess intra-
class correlation, measurements were performed on 50 CT scans by 
all raters blinded to each other’s measurements.
Blend sign is defined as an area of hypodensity adjacent to the 
hyperdense area of hematoma. The margin should be well-defined 
with a difference of at least 18 Hounsfield units between the 2 
areas (Figure 1).5 Black hole sign is an area of hypodensity that is 
completely encapsulated by an adjacent hyperdense area within a 
hematoma. The difference between the 2 areas should be at least 
28 Hounsfield units.6 Black hole sign is a subset of hypodensities, 
which can be of any Hounsfield unit and have distinct or indistinct 
border, as long as it is completed encapsulated by hyperdense area.8 
The island sign is characterized by presence of ≥3 separate small 
hematomas adjacent to the main hematoma or ≥4 small bubble- or 
sprout-like hematomas that are partially connected to the main he-
matoma.7 The signs were assessed by 4 independent raters (Z.K. 
Law, A. Ali, K. Krishnan, and A. Bischoff, medical student). All rat-
ers were trained and inter-rater reliability assessed using 70 scans, 
with raters blinded to each other’s ratings of signs.
Outcomes and Statistical Analysis
For this analysis, the outcomes were based on the TICH-2 CTA statis-
tical analysis plan16 as below.
Radiological Outcomes
Hematoma expansion is defined as increase in intraparenchymal he-
matoma volume on follow-up scan of >33% or > 6 mL from baseline 
hematoma. Total ICH expansion, defined as expansion of combined 
intraparenchymal and intraventricular hematoma volume of >33% or 
> 6 mL were analyzed as an outcome as well, as hematoma may have 
extended into intraventricular hemorrhage with a preserved intrapa-
renchymal hematoma volume.
In addition, we explored a composite outcome of hematoma 
progression, which was defined as intraparenchymal hematoma ex-
pansion or delayed intraventricular or subarachnoid extension or an 
absolute intraventricular hematoma expansion of ≥2 mL. When fol-
low-up scans were not available, early neurological deterioration (≥4 
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in Glasgow Coma Scale score of ≥ 2) or death before day-2 clinical 
assessment was considered hematoma progression. The rationale of 
including neurological deterioration or death is to avoid excluding 
patients who were unfit to have a follow-up scan.
Clinical Outcome
Unfavourable functional outcome, defined as a dichotomized modi-
fied Rankin Scale of 4 to 6, was the clinical outcome of interest.
Statistical Analysis
The sensitivity, specificity, positive and negative predictive values of 
each NCCT sign were analyzed individually. Fleiss kappa was used 
to measure inter-rater reliability as there were >2 independent raters. 
Descriptive analyses used Student t test, Mann-Whitney U test, and 
χ2 tests as appropriate. Multivariable logistic regression analyses were 
used to identify predictors of hematoma expansion and unfavourable 
functional outcome. The multivariable model included minimization 
factors as a priori variables and variables that were significant confound-
ers on univariate analysis (resulting in change of odds ratio ≥0.1 when 
included). We also performed sensitivity analyses using hematoma pro-
gression and total ICH expansion as outcomes. Ordinal logistic regres-
sion was performed as a sensitivity analysis to explore if presence of 
NCCT signs leads to a shift in modified Rankin Scale. To explore the 
diagnostic yield of NCCT signs in addition to known predictors, we per-
formed receiver operating characteristics analysis for known predictors 
of hematoma expansion (prior antiplatelet, baseline hematoma volume, 
and onset-to-CT time) and known predictors plus NCCT signs.
In addition, to explore the effect of tranexamic acid in patients 
with NCCT signs, a logistic regression model was constructed strat-
ified by status of NCCT signs. Ninety-five percent CIs are given and 
P of <0.05 were considered statistically significant. All analyses were 
performed using SPSS version 24 (IBM, Armonk, NY).
Results
Two thousand three hundred twenty-five participants were 
recruited into the trial from 124 centers in 12 countries. 
Baseline scans were available in 2273 patients (97.8%). Of 
these, 2077 (89.3%) participants also had follow-up CT scans 
and were included in the analysis of hematoma expansion 
(Figure I in the online-only Data Supplement). In addition, 
236 participants without follow-up scans had available neu-
rological deterioration or death status at 48 hours, and 2313 
patients (99.5%) were included in analysis of hematoma pro-
gression. Day 90 modified Rankin Scale was available in 2307 
patients (99.2%).
Five hundred seventy participants (27.4%) had hematoma 
expansion while 1259 patients (54.6%) had poor functional 
outcome. Participants with hematoma expansion had higher 
National Institutes of Health Stroke Scale, lower Glasgow 
Coma Scale, larger baseline hematoma volumes, more lobar 
location, more likely to have had antiplatelet therapy before 
ICH, a shorter onset-to-CT time, and less intraventricular 
hemorrhage (Table 1). Participants with hematoma expansion 
were more likely to have blend sign, black hole sign, island 
sign, and hypodensities on baseline imaging (Table 1).
The intraclass correlation for intraparenchymal hematoma 
volume was 0.94 (95% CI, 0.86–0.97). Intrarater Cohen κ for 
blend sign was 0.93 (95% CI, 0.79–1.00); black hole was 0.73 
(95% CI, 0.45–1.00); island sign 0.85 (95% CI, 0.57–1.00); 
and hypodensities 0.66 (95% CI, 0.43–0.90). The inter-rater 
Fleiss κ for blend signs was 0.60 (95% CI, 0.47–0.74); black 
hole sign 0.53 (95% CI, 0.41–0.64); island sign 0.64 (95% CI, 
0.53–0.75); and hypodensities 0.63 (95% CI, 0.39–0.86).
The prevalence of NCCT signs was: blend sign, 366 
(16.1%); black hole sign, 414 (18.2%); island sign, 200 
(8.8%); and hypodensities, 701 (30.2%). NCCT signs had low 
sensitivity (11.4%–39.5%) and high specificity (76%–93%) 
for hematoma expansion with island sign having the highest 
specificity but lowest sensitivity (Table I in the online-only 
Data Supplement). Similarly, NCCT signs had low sensi-
tivity (14%–39%) and high specificity (79.5%–97.6%) for 
poor functional outcome (Table I in the online-only Data 
Supplement). Baseline hematoma volumes were significantly 
larger in all NCCT signs; patients with black hole sign and 
hypodensities had shorter onset-to-CT time while a larger pro-
portion of patients with island signs were taking antiplatelet 
therapy (Table II in the online-only Data Supplement).
Univariate logistic regression showed that higher pre-
morbid modified Rankin Scale, prior antiplatelet therapy, lower 
Glasgow Coma Scale, lobar location, larger baseline hema-
toma volume, shorter onset-to-CT time as well as the presence 
of blend sign, black hole sign, island sign, and hypodensities 
increased the odds of hematoma expansion (Table 2). As there 
was significant overlap between black hole sign and hypoden-
sities, 2 different multivariable logistic regression models 
Figure 1. Shows the blend sign (left, white arrow), black hole sign (middle, black arrow), hypodensities (thick arrows), and island sign (right, black arrow 
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were constructed to predict hematoma expansion with model 
1 including black hole sign and model 2 including hypodensi-
ties (Table 2). Baseline hematoma volume, onset-to-CT time, 
and prior antiplatelet therapy were significant predictors of 
hematoma expansion. Of the NCCT signs, blend sign, black 
hole, and hypodensities were significant independent predic-
tors of hematoma expansion (Table 2). The island sign was 
no longer a significant predictor after adjusting for baseline 
hematoma volume. A combination of 1 or more NCCT signs 
did not improve the predictive probability of hematoma ex-
pansion (adjusted odds ratio [aOR], 1.57 [95% CI, 1.24–1.98]; 
P<0.001; not shown in table).
In the receiver operating characteristic analysis for he-
matoma expansion, the area under the curve for 3 predictors 
(hematoma volume, onset-to-CT time, and prior antiplatelet 
agent) was 0.654. Addition of blend and black hole signs, and 
blend sign and hypodensities improved the area under the 
curve minimally to 0.664 and 0.667, respectively.
As sensitivity analysis, we analyzed hematoma progression 
and total ICH volume expansion as outcomes. Multivariable 
logistic regression adjusting for variables used in the analysis 
for hematoma expansion showed that blend sign, black hole 
sign, and hypodensities were significant predictors of hema-
toma progression and total ICH expansion (Table III in the 
online-only Data Supplement).
Black hole sign, hypodensities, and island sign were sig-
nificant predictors of poor functional outcome after adjust-
ment of prognostic covariates (Table 3). A combination of 1 or 
more NCCT signs did not improve the predictive probability of 
poor functional outcome (aOR, 1.30 [1.01–1.66]; P=0.039; not 
shown in table). In the ordinal regression model, only the pres-
ence of black hole sign (aOR, 1.25 [1.01–1.56]; P=0.045) and 
Table 1. Baseline Characteristics in Patients With and Without Hematoma Expansion
Variables All Hematoma Expansion* No Hematoma Expansion* P Value
Patients randomized 2325 570 (27.4%) 1508 (72.6%)  
Age (y) 68.9 (13.8) 69.5 (13.9) 68.4 (13.7) 0.12
Sex (male) 1301 (56.0%) 332 (58.2%) 833 (55.2%) 0.22
Prestroke mRS (/5) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.012
Glasgow coma scale (/15) 15 (12–15) 14 (12–15) 15 (13–15) <0.001
NIHSS score (/42) 12 (7–19) 15 (9–20) 11 (6–17) <0.001
Systolic blood pressure, mm Hg 172.6 (27.2) 173.8 (29.8) 175.5 (29.4) 0.25
Intraventricular hemorrhage 704 (30.7%) 147 (25.9%) 465 (30.9%) 0.026
Hematoma location
  Supratentorial lobar 688 (29.6%) 206 (36.3%) 396 (26.4%) <0.001
  Supratentorial deep 1451 (62.4%) 332 (58.6%) 1011 (67.5%) <0.001
  Infratentorial 145 (6.2%) 29 (5.1%) 91 (6.1%) 0.41
 Previous antiplatelet therapy 611 (26.3%) 164 (28.8%) 357 (23.7%) 0.016
 Onset-to-CT time (median, h) 1.9 (1.4–2.8) 1.8 (1.3–2.5) 2.0 (1.4–3.0) <0.001
 Onset-to-CT time (mean, h) 2.3 (1.3) 2.0 (1.1) 2.4 (1.4) <0.001
Hematoma volume, mL
  ICH only (median, IQR) 13.3 (5.5–32.4) 21.4 (7.7–44.2) 10.7 (4.9–23.2) <0.001
  ICH only, categorical <0.001†
   <30 mL 1651 (72.6%) 345 (60.5%) 1213 (80.4%)  
   30–60 mL 365 (16.1%) 143 (25.1%) 184 (12.2%)  
   >60 mL 257 (11.3%)‡ 82 (14.4%) 111 (7.4%)  
  ICH+IVH (median, IQR) 16.3 (6.3–37.4) 23.8 (9.1–50.8) 13.2 (5.3–29.1) <0.001
Blend sign 366 (16.1%) 133 (23.3%) 180 (11.9%) <0.001
Black hole sign 414 (18.2%) 130 (22.8%) 218 (14.5%) <0.001
Hypodensities 701 (30.2%) 225 (39.5%) 365 (24.3%) <0.001
Island sign 200 (8.8%) 65 (11.4%) 102 (6.8%) 0.001
Data are mean (SD), median (IQR), or number (%). Statistics are χ2 test, Mann-Whitney U test, Student t test, and Mantel-Haenszel test of 
trend. ICH indicates intracerebral hemorrhage; IQR, interquartile range; IVH, intraventricular hemorrhage; mRS, modified Rankin Scale; and NIHSS, 
National Institutes of Health Stroke Scale.
*Assessments of hematoma expansion for 2077 patients with valid baseline and follow-up CT scans.
†Both χ2 and Mantel-Haenszel test of trend’s P<0.001.
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hypodensities (aOR, 1.33 [1.10–1.61]; P=0.003) resulted in sig-
nificant shift toward worse modified Rankin Scale (goodness-
of-fit test, P=0.92; proportional odds assumption not violated).
Overall, tranexamic acid reduced the risk of hematoma 
expansion (aOR, 0.77 [0.63–0.94]; P=0.01). Similarly, there 
was significant reduction in hematoma progression (aOR, 
0.71 [0.59–0.86]; P<0.001) and total ICH expansion (aOR, 
0.82 [0.67–0.99]; P=0.047). Logistic regression model strati-
fied by presence of NCCT signs did not show any significant 
interactions between the presence of signs and the benefit of 
tranexamic acid in reducing hematoma expansion (Figure 2). 
The effect of tranexamic acid on functional outcome, stratified 
by presence of NCCT signs is shown in Figure 3. Tranexamic 
acid did not significantly improve functional outcome regard-
less of the status of NCCT signs.
Discussion
In the largest randomized controlled trial of hemostatic 
therapy in ICH, we found that blend sign, black hole sign, 
and hypodensities were independent predictors of hematoma 
expansion. Nevertheless, addition of these signs to more es-
tablished predictors of onset-to-CT time, baseline hematoma 
volume, and antiplatelet therapy only marginally improved the 
area under the curve. The island sign was not a significant in-
dependent predictor of hematoma expansion.
Apart from Li et al who first described the blend and 
black hole signs, 2 large studies, Boulouis et al8 (n=1029) and 
Morotti et al11 (n=989) found them to be independent predic-
tors of hematoma expansion. A recent meta-analysis of 5 stud-
ies (2248 patients) found the pooled sensitivity and specificity 
of blend sign to be 0.28 (0.16–0.46) and 0.92 (0.88–0.95), 
respectively.17 A second meta-analysis of 5 studies (1495 
patients) reported a pooled sensitivity and specificity of 0.30 
(0.20–0.41) and 0.91 (0.87–0.94), respectively for black hole 
sign.18 Our study similarly found blend and black hole signs 
to be highly specific but not sensitive for prediction of hema-
toma expansion.
Hypodensities had been found to be a useful predictor of 
hematoma expansion and poor functional outcome as well.8,11 
There is significant overlap between black hole sign and 
hypodensities where black hole sign is a subset of hypoden-
sities. We found hypodensities to be more sensitive but less 
specific than black hole. The adjusted odd ratio in predicting 
hematoma expansion of hypodensities was similar to that for 
the black hole sign (aOR, 2.06 versus 2.01).
On the contrary, we did not find the island sign to be an 
independent predictor of hematoma expansion. The island 
sign was of particular interest as it was reported to be very 
specific, albeit less sensitive, than the other NCCT signs. The 
island sign was first reported as a predictor of hematoma ex-
pansion and poor functional outcome in a single-center study 
by Li et al.7 Similarly, we found the island sign to have high 
specificity but low sensitivity in detecting hematoma expan-
sion. However, after accounting for hematoma volume, the is-
land sign did not independently predict hematoma expansion. 
This may be because island sign was mostly present in large 
hematomas (64.6 mL in island sign positive versus 11.8 mL 
in island sign negative); hence, hematoma volume was a sig-
nificant confounder. Comparatively, the median volume was 
30 mL in island sign positive hematoma in study by Li et al.7 
Another reason is the prevalence of island sign in our cohort 
was relatively low (8.8% compared with 16% in study by Li 
et al) and the numbers may be inadequately powered to detect 
a difference.
Table 2. Binary Logistic Regression Analyses for Predictors of Hematoma Expansion
Variables Unadjusted OR P Value Adjusted OR (Model 1)* P Adjusted OR (Model 2)† P Value
Age 1.01 (1.00–1.01) 0.12 1.00 (1.00–1.01) 0.42 1.00 (1.00–1.01) 0.36
Sex (male) 1.13 (0.93–1.37) 0.22 1.31 (1.05–1.62) 0.016 1.32 (1.06–1.64) 0.012
Premorbid mRS 1.11 (1.01–1.21) 0.031 1.07 (0.96–1.19) 0.22 1.07 (0.96–1.19) 0.22
Systolic blood pressure, mm Hg 0.998 (0.995–1.001) 0.25 1.000 (0.996–1.004) 0.98 1.000 (0.997–1.004) 0.85
Glasgow Coma Scale (/15) 0.89 (0.85–0.93) <0.001 0.94 (0.89–0.99) 0.013 0.94 (0.89–0.99) 0.020
Previous antiplatelet therapy 1.31 (1.05–1.62) 0.016 1.27 (1.00–1.62) 0.053 1.28 (1.00–1.64) 0.048
Intraventricular hemorrhage 0.78 (0.63–0.97) 0.026 0.66 (0.52–0.84) 0.001 0.65 (0.51–0.83) 0.001
Supratentorial lobar 1.59 (1.29–1.95) <0.001 1.07 (0.81–1.40) 0.65 1.07 (0.81–1.40) 0.64
Baseline hematoma volume (per 
10 mL increase)
1.17 (1.13–1.22) <0.001 1.18 (1.12–1.26) <0.001 1.18 (1.12–1.27) <0.001
Onset-to-CT time, h 0.79 (0.73–0.86) <0.001 0.75 (0.69–0.83) <0.001 0.75 (0.69–0.83) <0.001
Treatment with tranexamic acid 0.83 (0.68–1.00) 0.053 0.77 (0.63–0.94) 0.010 0.76 (0.62–0.93) 0.009
Blend sign 2.25 (1.75–2.88) <0.001 1.53 (1.16–2.03) 0.003 1.49 (1.13–1.98) 0.005
Black hole sign 1.75 (1.37–2.23) <0.001 2.03 (1.34–3.08) 0.001 … …
Hypodensities 2.04 (1.66–2.51) <0.001 … … 2.06 (1.48–2.89) <0.001
Island sign 1.77 (1.28–2.46) 0.001 0.85 (0.57–1.26) 0.42 0.84 (0.57–1.25) 0.39
CT indicates computed tomography; mRS, modified Rankin Scale; and OR, odds ratio.
*Model 1: adjustment for all variables in unadjusted analysis except hypodensities with addition of black hole X hematoma volume interaction (P=0.004).
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Black hole sign, hypodensities, and island sign independ-
ently predicted poor functional outcome, although island sign 
did not predict hematoma expansion. Conversely, the blend 
sign that independently predicted hematoma expansion did not 
predict poor functional outcome. This suggests that although 
hematoma expansion increased the risk of poor functional out-
come, there were other factors that contributed to poor func-
tional outcome. This finding is in keeping with the trial main 
results where tranexamic acid significantly reduced hematoma 
expansion, early death (<7 days), and serious adverse events 
but did not improve functional outcome at day 90.4 We hypoth-
esize that one of the mechanisms may be the development of 
perihematomal edema. Hematomas with island sign have a 
larger surface area of contact with the surrounding tissue and 
this may contribute to more inflammation and cerebral edema.
While some of the NCCT signs are useful predictors of 
hematoma expansion, none of the signs reliably predicted 
clinical benefit of tranexamic acid. This again supports the 
hypothesis of alternate pathological process contributing to 
poor outcome. Although tranexamic acid reduced the risk of 
hematoma expansion, the effect of tranexamic acid is short 
lasting with a half-life of 3 hours.19 It is therefore unlikely 
that tranexamic acid will have any biological effect on events 
occurring later such as perihematomal edema. In addition, the 
number of patients with NCCT signs is relatively small and 
may be inadequately powered to detect a modest benefit of 
tranexamic acid. The usefulness of the CTA spot sign in pre-
dicting clinical benefit of tranexamic acid is being studied in 
a separate substudy.16
Our findings of male sex, lower Glasgow Coma Scale, ab-
sence of IVH, prior antiplatelet therapy, larger baseline he-
matoma volume, and shorter onset-to-CT time as independent 
predictors of hematoma expansion were consistent with pre-
vious studies.2 Notably, although intensive blood pressure 
Table 3. Binary Logistic Regression Analyses for Predictors of Death and Dependency (Dichotomized mRS Score of ≥4)
Variables Unadjusted OR P Value Adjusted OR (Model 1)* P Value Adjusted OR (Model 2)† P Value
Age 1.05 (1.05–1.06) <0.001 1.05 (1.04–1.06) <0.001 1.05 (1.04–1.06) <0.001
Sex (male) 0.61 (0.52–0.72) <0.001 0.76 (0.61–0.95) 0.016 0.77 (0.62–0.96) 0.019
Premorbid mRS 2.02 (1.81–2.25) <0.001 1.71 (1.50–1.95) <0.001 1.71 (1.50–1.95) <0.001
Systolic blood pressure, mm Hg 0.998 (0.995–1.0) 0.104 1.000 (0.996–1.003) 0.81 1.000 (0.996–1.003) 0.87
Glasgow Coma Scale (/15) 0.66 (0.62–0.70) <0.001 0.77 (0.72–0.82) <0.001 0.77 (0.73–0.82) <0.001
Previous antiplatelet therapy 2.20 (1.81–2.67) <0.001 1.32 (1.02–1.71) 0.036 1.33 (1.02–1.72) 0.034
Intraventricular hemorrhage 3.43 (2.82–4.18) <0.001 2.24 (1.76–2.87) <0.001 2.26 (1.77–2.89) <0.001
Supratentorial lobar 1.55 (1.29–1.86) <0.001 0.39 (0.29–0.53) <0.001 0.40 (0.29–0.54) <0.001
Baseline hematoma volume (per 
10 mL increase)
1.58 (1.49–1.68) <0.001 1.60 (1.47–1.74) <0.001 1.60 (1.47–1.76) <0.001
Onset-to-CT time, h 0.91 (0.85–0.97) 0.003 0.87 (0.80–0.94) 0.001 0.87 (0.80–0.94) 0.001
Treatment with tranexamic acid 0.99 (0.84–1.16) 0.89 0.87 (0.71–1.08) 0.23 0.87 (0.70–1.07) 0.18
Blend sign 1.95 (1.54–2.47) <0.001 1.05 (0.76–1.47) 0.76 1.04 (0.75–1.45) 0.81
Black hole sign 2.49 (1.97–3.15) <0.001 1.52 (1.10–2.11) 0.012 … …
Hypodensities 2.50 (2.07–3.03) <0.001 … … 1.37 (1.05–1.78) 0.019
Island sign 7.29 (4.68–11.35) <0.001 2.59 (1.21–5.55) 0.014 2.21 (1.04–4.67) 0.037
CT indicates computed tomography; mRS, modified Rankin Scale; and OR, odds ratio.
*Model 1: adjustment for all variables on unadjusted analysis except hypodensities with addition of black hole X island interaction.
†Model 2: adjustment for all variables on unadjusted analysis except black hole sign with addition of hypodensities X island interaction.
Figure 2. Effect of tranexamic acid on he-
matoma expansion, stratified by presence of 
noncontrast computed tomography signs. aOR 
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lowering can reduce hematoma expansion,20 systolic blood 
pressure on admission per se was not a predictor of hematoma 
expansion, a finding replicated in our study.2
The strength of the study is the large sample size and good 
availability of CT scans, making this the largest imaging anal-
ysis in ICH. There is a wide range of hematoma volumes from 
very small to very large hematoma reflective of real-world 
patients with ICH. To account for intraventricular extension 
and missing data, we performed exploratory analysis using 
total ICH expansion and a composite outcome of hematoma 
progression (data available in 99.5%) as outcomes. The analy-
ses yielded similar results hence the conclusion is robust.
One limitation of this study is the inter-rater agreement is 
only moderate (κ, 0.53–0.64). The raters were from a range of 
background (physicians, radiographer, and medical student). 
Although all raters were trained before commencing assess-
ment, the interpretation of the NCCT signs may not be as ac-
curate as other studies where the assessments were usually 
performed by only 2 expert raters.5–7,11 Having more raters also 
reduced agreement as it is less likely for 4 raters to completely 
agree on the presence of signs compared with 2 raters. However, 
our interpretation represents a real world scenario where the rat-
ers are likely to have different background and experience.
Recently, there is much enthusiasm in exploring the role of 
NCCT signs in predicting hematoma expansion. We found pre-
viously established factors of baseline hematoma volume and 
onset-to-CT time to be more significant predictors of hema-
toma expansion. Addition of NCCT signs only improved the 
area under the curve minimally by 0.01 to 0.013. Hematoma 
volume may be the most important CT marker of hematoma 
expansion and may be used to better select in future hemostatic 
trials. Although we have used semiautomated segmentation 
technique for the volume measurement, simple clinical tool 
such as the ABC/2 method has been shown previously to be a 
reliable and feasible method in the context of clinical trials.21 In 
view of its prognostic value, calculation of hematoma volume 
should perhaps be recommended as a routine clinical practice.
Conclusions
Blend sign, black hole sign, and hypodensities predict hema-
toma expansion while black hole sign, hypodensities, and is-
land sign predict poor functional outcome. NCCT signs did 
not predict a better response to tranexamic acid.
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